Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To (1) determine the value of the recently proposed criteria of neuromyelitis optica (NMO) spectrum disorder (NMOSD) that unify patients with NMO and those with limited forms (NMO/LF) with aquaporin-4 immunoglobulin G (AQP4-IgG) antibodies; and (2) investigate the clinical significance of the serologic status in patients with NMO. METHODS: This was a retrospective, multicenter study of 181 patients fulfilling the 2006 NMO criteria (n = 127) or NMO/LF criteria with AQP4-IgG (n = 54). AQP4-IgG and myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) antibodies were tested using cell-based assays. RESULTS: Patients were mainly white (86%) and female (ratio 6.5:1) with median age at onset 39 years (range 10-77). Compared to patients with NMO and AQP4-IgG (n = 94), those with NMO/LF presented more often with longitudinally extensive transverse myelitis (LETM) (p < 0.001), and had lower relapse rates (p = 0.015), but similar disability outcomes. Nonwhite ethnicity and optic neuritis presentation doubled the risk for developing NMO compared with white race (p = 0.008) or LETM presentation (p = 0.008). Nonwhite race (hazard ratio [HR] 4.3, 95% confidence interval [CI] 1.4-13.6) and older age at onset were associated with worse outcome (for every 10-year increase, HR 1.7, 95% CI 1.3-2.2). Patients with NMO and MOG-IgG (n = 9) had lower female:male ratio (0.8:1) and better disability outcome than AQP4-IgG-seropositive or double-seronegative patients (p < 0.001). CONCLUSIONS: In patients with AQP4-IgG, the similar outcomes regardless of the clinical phenotype support the unified term NMOSD; nonwhite ethnicity and older age at onset are associated with worse outcome. Double-seronegative and AQP4-IgG-seropositive NMO have a similar clinical outcome. The better prognosis of patients with MOG-IgG and NMO suggests that phenotypic and serologic classification is useful.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649 · cited 5×
“These criteria are based on the presence or absence of AQP4-IgG and on the assumption that patients with limited forms (NMO/LF) will develop typical NMO over time.(2,3) However, in some patients the interval between the disease-defining events of optic neuritis and myelitis and conversion to NMOmay be years or decades.”
BackgroundResultInfluentialBarkhof, F. (1997) · Brain · doi:10.1093/brain/120.11.2059 · Cited by 1,251
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
Sato, D. K., Callegaro, D., Lana-Peixoto, M. A., Waters, P. J., Jorge, F. M. D. H., Takahashi, T., Nakashima, I., Apostolos-Pereira, S. L., Talim, N., Simm, R. F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000101 · Cited by 850
Kitley, J., Waters, P., Woodhall, M., Leite, M. I., Murchison, A., George, J., Küker, W., Chandratre, S., Vincent, A., & Palace, J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5857 · Cited by 597
Kitley, J., Leite, M. I., Nakashima, I., Waters, P., McNeillis, B., Brown, R., Takai, Y., Takahashi, T., Misu, T., Elsone, L., et al. (2012) · Brain · doi:10.1093/brain/aws109 · Cited by 438
Cited by
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
Yamamura, T., Kleiter, I., Fujihara, K., Palace, J., Greenberg, B., Zakrzewska-Pniewska, B., Patti, F., Tsai, C.-P., Saiz, A., Yamazaki, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901747 · Cited by 664
Self-citationMyelin oligodendrocyte glycoprotein antibodies in neurological disease
Reindl, M., & Waters, P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0112-x · Cited by 626
Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study
Cobo-Calvo, A., Ruiz, A., Maillart, E., Audoin, B., Zephir, H., Bourre, B., Ciron, J., Collongues, N., Brassat, D., Cotton, F., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005560 · Cited by 538
Self-citationTraboulsee, A., Greenberg, B. M., Bennett, J. L., Szczechowski, L., Fox, E., Shkrobot, S., Yamamura, T., Terada, Y., Kawata, Y., Wright, P., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30078-8 · Cited by 513
Hacohen, Y., Wong, Y. Y., Lechner, C., Jurynczyk, M., Wright, S., Konuskan, B., Kalser, J., Poulat, A. L., Maurey, H., Ganelin-Cohen, E., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4601 · Cited by 423
Metadata
- Authors
- Sepúlveda, M., Armangué, T., Sola-Valls, N., Arrambide, G., Meca-Lallana, J. E., Oreja-Guevara, C., Mendibe, M., Alvarez de Arcaya, A., Aladro, Y., Casanova, B., Olascoaga, J., Jiménez-Huete, A., Fernández-Fournier, M., Ramió-Torrentà, L., Cobo-Calvo, A., Viñals, M., de Andrés, C., Meca-Lallana, V., Cervelló, A., Calles, C., Rubio, M. B., Ramo-Tello, C., Caminero, A., Munteis, E., Antigüedad, A. R., Blanco, Y., Villoslada, P., Montalban, X., Graus, F., Saiz, A., Spanish NMO Study Group, Borrego, L., Villaverde, F. J. J., Sempere, Á. P., Brieva, L., Bonet, M., González-Platas, M., Puma, D. L., Llufriu, S., Martínez, E. H., Boyero, S., Benito-León, J., López, J. C., Robles, R., Foronda, J., Navarró, L., Millán, T., Hervás, M., Tallón, A., Puertas, I., Huertas, N., Redondo, L., Santos, S., Palmí, I., Salgado, M., Martínez, J. E., Rubio, M. A., Oterino, A., Ara, R., Villaverde, R., Ayuso, T., Erro, E., Marco, M., Villar, L., Álvarez-Cermeño, J. C., Agüera, E., Bescansa, E., Yugüeros, I., Tola, M. A., Orviz-García, A., del Haro, T., Bestué, M., Gómez, M., Querol, L., Rodríguez, E., Ballabriga, J., Tintoré, M., Castilló, J., Rio, J., Muñoz, D., Midaglia, L., Carreón-Guarnizo, E., Casado, J. L., Uclés, A., & García-Montero, R.
- Venue
- Neurology Neuroimmunology & Neuroinflammation
- Published
- 2016-06
- Volume
- 3
- Issue
- 3
- Pages
- e225-e225
- ISSN
- 2332-7812 (ISSN-L)
- OpenAlex
- W2342230608
- Cited by
- 154
- References
- 6
- FWCI
- 16.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. https://app.cochat.ai/papers/10.1212/nxi.0000000000000225
- The paper
- Sepúlveda, M., Armangué, T., Sola-Valls, N., Arrambide, G., Meca-Lallana, J. E., Oreja-Guevara, C., Mendibe, M., Alvarez de Arcaya, A., Aladro, Y., Casanova, B., Olascoaga, J., Jiménez-Huete, A., Fernández-Fournier, M., Ramió-Torrentà, L., Cobo-Calvo, A., Viñals, M., de Andrés, C., Meca-Lallana, V., Cervelló, A., . . . García-Montero, R. (2016). Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. Neurology Neuroimmunology & Neuroinflammation. https://doi.org/10.1212/nxi.0000000000000225
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.